Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials

This article provides an overview of advances in treatment strategies for IgG4-RD, shedding light upon the characteristics of inebilizumab and results of the clinical trials. Various targeted therapies under the development are expected to overcome limitations in safety and efficacy of glucocorticoids and to reduce risk of organ damage and fibrosis.

Authors

Institutions

Publication Details

Journal
Expert Opinion on Biological Therapy
Published
2026-02-01
DOI
https://doi.org/10.1080/14712598.2026.2634052
Primary Topic
IgG4-Related and Inflammatory Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials

Yoshiya Tanaka
Expert Opinion on Biological Therapy
IgG4-Related and Inflammatory Diseases
article

Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials

Yoshiya Tanaka
article en

Abstract

This article provides an overview of advances in treatment strategies for IgG4-RD, shedding light upon the characteristics of inebilizumab and results of the clinical trials. Various targeted therapies under the development are expected to overcome limitations in safety and efficacy of glucocorticoids and to reduce risk of organ damage and fibrosis.

Expert Opinion on Biological TherapyVol. 26(2)
University of Occupational and Environmental Health Japan (JP)
Good health and well-being
Openalex Percentile: Top 50%
IgG4-Related and Inflammatory Diseases
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials — Yoshiya Tanaka · Expert Opinion on Biological Therapy (2026) | TGRS Research Map | TGRS